非小细胞肺癌患者外周血及胸腔积液表皮生长因子基因突变的对比研究
摘要
肺癌是目前发病率和病死率最高的肿瘤之一,其中非小细胞肺癌(NSCLC)约占肺癌的80%,恶性程度高[1]。外周血和胸腔积液作为检测晚期NSCLC患者表皮生长因子受体(EGFR)基因突变的标本来源,相较传统的组织标本方便、快捷,给患者带来的创伤更少。
出处
《中国药物与临床》
CAS
2020年第14期2336-2338,共3页
Chinese Remedies & Clinics
基金
山西省卫生计生委科研课题(201201007)。
参考文献3
-
1刘根贤,慕进勇,张守翠.非小细胞肺癌患者胸水与外周血检测EGFR基因突变的比较[J].国际检验医学杂志,2016,37(7):985-987. 被引量:6
-
2陈思远,陈志红,郭爱林,苏健,黄迎,陈世良,张绪超,杨学宁,杨衿记,吴一龙.变性高效液相色谱法检测多种途径获取的非小细胞肺癌组织表皮生长因子受体基因突变[J].中国肺癌杂志,2010,13(9):850-855. 被引量:4
-
3李辰晨,吴建中,王卓,冯继锋.直接测序法和ARMS法检测非小细胞肺癌表皮生长因子受体基因突变的比较[J].中国肺癌杂志,2014,17(8):606-611. 被引量:3
二级参考文献47
-
1周冬辰,李龙芸,崔全才,王孟昭,张力,穆新林.变性高效液相色谱法分析中国人非小细胞肺癌、结直肠癌中表皮生长因子受体突变情况和临床意义[J].癌症进展,2006,4(5):462-466. 被引量:5
-
2Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N EnglJ Med, 2004, 350(21): 2129-2139.
-
3PaezJG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 2004, 304(5676): 1497-1500.
-
4Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA, 2004, 101(36): 13306-13311.
-
5Han SW, Kim TY, Hwang PG, et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol, 2005, 23 (11): 2493-2501.
-
6Xiao W, Oefner PJ. Denaturing high-performance liquid chromatography: A review. Hum Mutat, 2001, 17(6): 439-474.
-
7Kleymenova E, Muga S, Fischer S, et al. Application of high-performance liquid chromatography-based analysis of DNA fragments to molecular carcinogenesis. Mol Carcinog, 2000, 29(2): 51-58.
-
8De SD, Wittwer CT. Monitoring hybridization during polymerase chain reaction.J Chromatogr B Biomed Sci AppI, 2000, 741(1): 3-13.
-
9Bai H, Mao L, Wang HS, et al. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages ⅢB to Ⅳ non-small-cell lung cancer. J Clin Oncol, 2009, 27(16): 2653-2659.
-
10Cohen V, Agulnik JS, Jarry J, et al. Evaluation of denaturing high- performance liquid chromatography as a rapid detection method for identification of epidermal growth factor receptor mutations in non small- cell lung cancer. Cancer, 2006, 107( 12): 2858-2865.
共引文献10
-
1张鑫宇,刘皈阳,祝晓光,王伟兰.非小细胞肺癌EGFR突变的检测方法[J].中国肺癌杂志,2011,14(3):297-302. 被引量:3
-
2王向迎,刘友如,牛艳洁,江银玲,韩宝惠,姜丽岩.非小细胞肺癌EGFR基因突变检测技术进展[J].国际呼吸杂志,2012,32(10):793-797. 被引量:6
-
3丁海艳,赖章超,栾丽,宋鑫.非小细胞肺癌EGFR-TKI基因检测[J].实用肿瘤杂志,2012,27(5):468-474. 被引量:1
-
4杨建平.百合固金汤治疗肺癌晚期并发胸水的临床观察[J].光明中医,2018,33(21):3164-3166. 被引量:5
-
5张怡,王富禹.检测非小细胞肺癌的表皮生长因子受体方法研究进展[J].生物技术通讯,2016,27(6):892-894. 被引量:1
-
6杨英姿,唐洪屈,刘灿容,李思旋,杨廉方.中药外用剂治疗非小细胞肺癌导致的胸水的临床应用研究[J].内蒙古中医药,2017,36(2):85-85.
-
7刘田田,毕经旺,王俊.非小细胞肺癌EGFR突变与脑转移的关系[J].肿瘤防治研究,2017,44(3):189-192. 被引量:15
-
8禹乐,朱启淦,杨立民,温路生,魁国菊,潘羡心,孟加榕.胸水细胞块EGFR基因突变检测在非小细胞肺癌中的临床意义[J].山西医科大学学报,2017,48(5):462-466. 被引量:11
-
9薛英杰,贾靖,吴杨,邵董,赵美芝,薛英超.培美曲塞和吉西他滨联合阿法替尼治疗晚期非小细胞肺癌临床效果及安全性分析[J].临床误诊误治,2020,33(2):57-60. 被引量:10
-
10赵俊军,李平.胸水中EGFR基因突变检测在酪氨酸激酶抑制剂治疗肺腺癌中的应用[J].中国实用医药,2020,15(25):204-206.